Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate
Sd. Boden et al., Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate, SPINE, 24(12), 1999, pp. 1179-1185
Study Design. A nonhuman primate lumbar intertransverse process arthrodesis
model was used to evaluate recombinant human bone morphogenetic protein 2
(rhBMP-2) in a hydroxyapatite-tricalcium phosphate (HA-TCP) carrier as a co
mplete bone graft substitute.
Objectives. To assess the ability of a ceramic material to serve as a carri
er for various doses of rhBMP-2 as a bone graft substitute in a primate mod
el of posterolateral intertransverse process spinal fusion after laminectom
y.
Summary of Background Data. The reported nonunion rates for posterolateral
lumbar spine fusion with autogenous iliac crest bone range from 5-35%. Reco
mbinant human bone morphogenetic protein 2 has shown potential to serve as
a bone graft substitute for posterolateral intertransverse process spine fu
sion. Although a resorbable collagen sponge was a suitable carrier in rabbi
ts and dogs, it was too compressible for the paraspinal muscles in rhesus m
onkeys. This failure of the collagen carrier has prompted evaluation of the
feasibility of an alternative carrier material and the required dose of rh
BMP-2.
Methods. Twenty-one adult rhesus monkeys underwent a laminectomy at L4-L5 f
ollowed by bilateral intertransverse process arthrodesis via the same midli
ne incision (n = 16) or a minimally invasive video-assisted posterolateral
approach (n = 5). Bone graft implants on each side consisted of either 5 cm
(3) of autogenous iliac crest bone or 60:40 HA-TCP blocks (1.2 x 0.5 x 3.7
cm) loaded with a solution containing 0, 6, 9, or 12 mg of rhBMP-2 per side
. The monkeys were killed 24 weeks after surgery. Inspection, manual palpat
ion, radiography, and histology were used to assess fusion and to detect an
y bony-growth into the laminectomy defect.
Results. Fusion was not achieved in any of the monkeys treated with autogen
ous iliac crest bone graft. Both of the monkeys treated with the HA-TCP blo
cks with 0 mg rhBMP-2 achieved fusion. All 15 monkeys treated with the HA-T
CP blocks and either of the three doses of rhBMP-2 achieved solid fusion. T
wo animals had extension of the fusion on one side because of malpositioned
ceramic block. The results in animals fused via the minimally invasive vid
eo-assisted technique were the same as in those fused with the open techniq
ue. Histologic analysis showed some ingrowth of bone into the ends but not
through the ceramic block in the absence of rhBMP-2. When the ceramic block
s were loaded with rhBMP-2 there was a dose-dependent increase in the amoun
t and quality of bone throughout the ceramic carrier based on qualitative a
ssessment. No significant bone encroachment on the exposed thecal sac throu
gh the laminectomy defect was observed in any of the monkeys.
Conclusion. Hydroxyapatite-tricalcium phosphate proved to be a suitable car
rier for rhBMP-2 in the posterolateral spine fusion model in rhesus monkeys
. Even in the presence of a laminectomy defect, there was no evidence of bo
ne induction outside the confines of the ceramic carrier.